Multiplex genome editing: companies, startups and research

The organization data lists 174 companies and 22 startups in the field. Colossal Biosciences describes a multiplex genome-editing pipeline for combinatorial trait engineering. Lart Bio works on livestock genetic engineering, while Qihan Biotech applies genome editing to cell therapies and xenotransplantation; those descriptions do not establish that all their work is specifically multiplex.

Colossal Biosciences is a notable startup example because its described work includes a multiplex pipeline for combinatorial trait engineering. The startup list also includes Lart Bio and Qihan Biotech, whose profiles describe livestock engineering and edited cell platforms, respectively. The available facts do not provide a comparative assessment of commercial prospects or establish a ranking among startups.

The Chinese Academy of Sciences CAS leads the listed research organizations with 98 recent-window documents, followed by Harvard University with 88 and the University of California with 79. Other active groups include the Chinese Academy of Agricultural Sciences, Zhejiang University and the University of Pennsylvania, which are associated with crop editing and guide-array research.

Recorded grants total $63,509,304 across 89 grants since 2020. This grant figure is distinct from the separate funding-round aggregate of $58,762,240,137 across 38 rounds, which includes entries not clearly attributable to multiplex genome editing. Treat the grant total as the more relevant funding indicator, while recognizing that the underlying records may include adjacent work.

The Broad Institute Inc. is the leading listed patent holder, with 7 patents. DuPont Pioneer and Integrated DNA Technologies, Inc. each have 4, while Tsinghua University, the Massachusetts Institute of Technology and the Trustees of Columbia University each have 3. These figures describe the patent-holder list in the available facts.

Patent activity is declining in the latest window: 106 patents are recorded, with growth of -58.7%. By contrast, publications reached 1,379 last year and grew by 43.8%. The difference suggests research output is expanding faster than patenting in this dataset, though the figures alone do not explain whether this reflects filing delays, changing strategies or shifts in the methods being developed.

Recent developments include the University of Pennsylvania's Drive-and-Process guide RNA arrays for multiplexed base and prime editing in September 2026, and a turnip mosaic virus-based guide RNA delivery system for plants that month. In July 2026, Zhejiang University researchers reported optimized tRNA processing and a TREX2–SpCas9 fusion to improve multiplex editing efficiency in plants.

The largest listed application is human cell and gene therapy, with 676 documents, followed by animal breeding and models with 483. Other areas include functional genomics, crop improvement and microbial engineering. Recent work also applies multiplex editing to crop traits, industrial microbial strains and research platforms for xenotransplantation.

The United States leads the country breakdown with 6,646 documents, or 50.1%, followed by China with 3,687, or 27.8%. The United Kingdom ranks next with 1,900 documents. The country figures overlap across organizations and should be read as activity indicators, not as exclusive shares of global research.